These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7082859)

  • 1. Prognostic factors in COPP-treated patients with Hodgkin's disease.
    Gassmann W; Perenyi L; Schmitz N; Kayser W; Pralle H; Löffler H
    Blut; 1982 Jun; 44(6):339-48. PubMed ID: 7082859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.
    Bang SM; Cheong JW; Yang WI; Hahn JS
    Yonsei Med J; 2005 Jun; 46(3):425-30. PubMed ID: 15988816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
    Morgenfeld MC; Pavlovsky A; Suarez A; Somoza N; Pavlovsky S; Palau M; Barros CA
    Cancer; 1975 Oct; 36(4):1241-9. PubMed ID: 1100220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
    Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
    Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen].
    Höffken K; Ippisch A; Pfeiffer R; Becher R; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1985 Apr; 110(16):618-23. PubMed ID: 3838719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
    Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
    Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience.
    Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R
    Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group.
    Loeffler M; Pfreundschuh M; Hasenclever D; Hiller E; Gerhartz H; Wilmanns W; Rohloff R; Rühl U; Kühn G; Fuchs R
    Blut; 1988 Jun; 56(6):273-81. PubMed ID: 2454691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3].
    Diehl V; Pfreundschuh M; Löffler M; Smith K; Rühl U; Georgii A; Hiller E; Gerhartz H
    Onkologie; 1987 Apr; 10(2):62-6. PubMed ID: 2438613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of Hodgkin's lymphomas. Results of the German Hodgkin's Disease Study Group].
    Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S; Bartels H
    Onkologie; 1988 Feb; 11(1):48-52. PubMed ID: 2452393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
    Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
    J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
    Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
    J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.